Congresswoman Maria Elvira Salazar Reports Stock Purchases of Up to $190,000 in Merck, Berkshire, Moderna, and SpaceX

U.S. Representative Maria Elvira Salazar reported stock purchases in individual companies—including Merck (MRK), Berkshire Hathaway Class B shares (BRK.B), Moderna (MRNA), and Space Exploration Technologies (ticker SPCX)—totaling between $4,005 and $195,000.[1] All transactions are classified as “Purchase (P),” indicating increased exposure by the Representative or her family to healthcare and pharmaceutical stocks, a major holding company, and space-related equities, with a 33-day lag between the transaction dates and the disclosure date.[1]

This transaction portfolio is evenly distributed across pharmaceutical and biotech (Merck, Moderna), a large investment holding company (Berkshire Hathaway), and an unlisted space industry firm (Space Exploration Technologies), which could heighten the interest of investors and regulators seeking to examine potential conflicts of interest during sector-specific regulation or budget review processes.[1] Notably, trades related to Merck and Space Exploration Technologies were each reported twice, providing market participants tracking repeat purchase volumes and timings for the same stocks with concrete reference data.[1]

거래 내용 요약

All transactions took place between August 7 and August 19, 2026, were reported to Congress on September 1, 2026, and publicly disclosed on September 9, 2026.[1] The reporting thresholds range from $1,001 to $50,000, confirming only that the actual investment amounts per company fall within these bands.[1]

마리아 엘비라 살라자르 의원 주식 거래 내역[1]

Transaction Date	Asset	Ticker	Transaction Type	Amount Range	Notes
2026-08-07	Berkshire Hathaway Inc. New Common Stock (BRK.B) [ST]	BRK.B	Purchase (P)	$1,001 – $15,000	Increased exposure to a large investment holding company
2026-08-12	Space Exploration Technologies Corp. – Class A Common Stock (SPCX) [ST]	SPCX	Purchase (P)	$1,001 – $15,000	First purchase of private space-related equity
2026-08-12	Space Exploration Technologies Corp. – Class A Common Stock (SPCX) [ST]	SPCX	Purchase (P)	$1,001 – $15,000	Second purchase of the same stock
2026-08-19	Merck & Company, Inc. Common Stock (MRK) [ST]	MRK	Purchase (P)	$15,001 – $50,000	First purchase of a major pharmaceutical company
2026-08-19	Merck & Company, Inc. Common Stock (MRK) [ST]	MRK	Purchase (P)	$15,001 – $50,000	Second purchase of the same stock
2026-08-19	Moderna, Inc. – Common Stock (MRNA) [ST]	MRNA	Purchase (P)	$1,001 – $15,000	mRNA vaccine and biotech-related

투자자·시장에의 의미

This filing indicates that Representative Salazar is allocating capital simultaneously to pharmaceutical and biotech, the space industry, and a major investment holding company, and that the two separate purchases on the same day of Merck and Space Exploration Technologies shares can be interpreted as relatively increasing her exposure to individual stock risk.[1] This information serves as direct reference material for shareholders and market participants to assess the Representative’s interests and potential conflicts when Congress deliberates on healthcare and pharmaceutical policy, space and defense budgets, or regulation of large financial and investment firms.[1]

Additionally, the 33-day lag between transaction dates and the public disclosure highlights the limitations of information timeliness for investors seeking to track real-time links with short-term policy announcements or legislative developments.[1] While this disclosure does not directly alter the corporate fundamentals, it enhances transparency around Congressional interests in Merck (MRK), Berkshire Hathaway Class B (BRK.B), Moderna (MRNA), and Space Exploration Technologies (SPCX), providing additional risk and governance insights for investors holding or monitoring these stocks.[1]